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(GC) are interchangeable; however, the molecular differ-
ences driving tumorigenesis for these cancers remain poorly
defined. The present study utilized biomarker analysis of
actionable targets for IHC and GC to distinguish them and
potentially refine current treatment strategies.
217 IHC and 28 GC specimens referred to Caris Life Sci-
ences between 2009 thru 2012 were evaluated. Specific
testing by immunohistochemical analysis for 17 different
biomarkers was performed. In the collective cohort
(n = 245), actionable targets included: 95% low TS, 82% low
RMM1, and 74% low ERCC1, indicating potential suscep-
tibility to fluoropyrimidines/capecitabine, gemcitabine, and
platinum agents, respectively. Additional non-NCCN com-
pendium targets included TOPO1 (53.3% high, irinotecan),
MGMT (50.3% low, temozolomide), TOP2A (33% high,
anthracyclines), and PGP (30.1% low, taxanes). Subgroup
analysis by tumor origin demonstrated a differential
biomarker expression pattern with a higher frequency of IHC
tumors showing low levels of TS (99% vs. 72%, p < 0.0001),
and RRM1 (85% vs. 64%, p = 0.021) when compared to GC.
Conversely a greater frequency of GC demonstrated high
levels of TOPO1 (76% vs. 50%, p = 0.018) versus IHC,
indicating a potential increased benefit from irinotecan.
Biomarker analysis possesses the capacity to identify addi-
tional targets for which established agents are available. Dif-
ferences in molecular profiles of IHC and GC provide
evidence that the two are distinct diseases and require differ-
ent treatments.
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Background: Liver dome tumors are not traditionally ame-
nable to minimally invasive hepatectomy (MIH) due to
superior/central location. In order to increase the number of
lesions amenable to MIH, new approaches are needed. Addi-
tional challenges in MIH include loss of 3D visualization and
tactile perception for intraoperative guidance within the
intra-hepatic anatomy.
Methods: This video includes the use of a pre-operative 3D
virtual model and intra-operative augmented reality (AR)
navigation to facilitate trans-thoracic MIH of the liver
dome.
Results: We present a 52 year-old gentleman with a 3 cm
isolated hepatocellular carcinoma in segment 8. A trans-
thoracic approach was chosen to allow for MIH. The video
begins with presentation of 3D reconstruction and virtual
resection planning. Principles of AR are detailed. The surgi-
cal steps include positioning and triangulation of thoracic
ports under AR guidance, followed by trans-diaphragmatic
tumor localization, identification of the phrenotomy site, and
planning of margins using intra-operative ultrasound com-
bined with AR. The parenchyma is transected with bipolar
radiofrequency ablation and ultrasonic scalpel. After closure
of diaphragm, the specimen is extracted through an enlarged
thoracic port, and a chest tube is placed. The procedure was
well tolerated. The chest tube was pulled on day 3 and dis-
charge occurred on day 4.
Conclusion: This video of liver resection for challenging
tumor localization illustrates a different, safe, and valuable
approach to MIH. It highlights how 3D virtual resection
planning and AR can enhance and facilitate complex MIH,
thereby easing the transition into the minimally invasive era
for liver surgery.
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A PANCREAS CANCER SCREENING
PROGRAM WITHIN A HIGH VOLUME
PANCREATIC CANCER PROGRAM
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Background: Approximately 10% of pancreatic cancer
(PC) may be hereditary and screening of high risk individuals
has been recommended. Herein we describe the establish-
ment of a comprehensive multidisciplinary screening
program.
Methods: Screening criteria included the presence of PC
in: 2+ first-degree relatives (FDR), or 3+ any degree relatives
(ADR), or any known hereditary cancer syndrome with
increased PC risk. Lifetime PC risk was calculated using the
CancerGene PancPro software. The clinic provided genetic
counseling and nutrition/wellness education. MRI imaging
was selectively recommended based the lifetime PC risk.
Results: Forty-three patients were screened; 65% were
female and the median age was 54 (IQR:11). Family history
was significant for two FDR in 12 (28%) patients and three
ADR in 11 (26%). Median age of the earliest affected family
member with PC was 59 (IQR:15). Hereditary cancer syn-
dromes were present in 18 (41%) patients: BRCA1(3),
BRCA2(6), MLH1(1), PMS2(1), PALB2(1), ATM(1),
CDKN2A(4) and STK11(1). Median PancPro estimated life-
time risk of screened patients was 7% (IQR:6). Twenty-two
(51%) of 43 patients had a lifetime risk over 10%. Elevated
Abstracts 3
© 2015 The Authors
HPB © 2015 Americas Hepato-Pancreato-Biliary AssociationHPB 2015, 17 (Suppl. 1), 1–80
CA19-9 or HbA1c was detected in 2 (5%) and 4 (9%)
patients, respectively. Screening MRI was obtained in 37
(86%) of 43 patients and 10 (27%) of the 37 had pancreatic
cystic lesions. No patient has undergone surgical resection of
a pancreatic lesion.
Conclusions: Initiation of a high risk PC screening clinic
identifies patients with radiographic or biochemical abnor-
malities for which surveillance is necessary. Guidelines for
the frequency of surveillance and indications for surgery are
needed.
LO-A.02 HAS SURVIVAL IMPROVED
FOLLOWING RESECTION FOR
PANCREATIC ADENOCARCINOMA?
A. S. Rosemurgy, R. Klein, C. Ryan, P. Sukharmwala,
B. Sadowitz, K. Luberice, S. B. Ross
Florida Hospital Tampa, Tampa, FL
Introduction: Billions of dollars have been spent on the
research and treatment of pancreatic cancer. This study was
undertaken to determine if survival after resection of pancre-
atic adenocarcinoma has been extended over the past two
decades.
Methods: The SEER database was queried for patients who
underwent pancreatectomy for pancreatic adenocarcinoma
from 1992 through 2010. AJCC Stage and survival were
determined for each patient. Data were analyzed using
Mantel-Cox test and linear regression. Significance was
accepted at p < 0.05.
Results: 15,604 patients underwent pancreatectomy from
1992 through 2010. Survival improved from 1992 through
2010 (p < 0.0001), as denoted in Figure 1 with the patients
divided into three cohorts for illustrative purposes (1992–97,
N = 1,846; 1998–2003, N = 4,528; 2004–10, N = 9,230).
Similarly, median survival increased 1992 through 2010 (14
vs. 15 vs. 18 months for the cohorts, p < 0.0001). However,
5-year survival rates did not change 1992 through 2010
(14.4% vs. 15.2% vs. 17.0% for the cohorts; p = 0.07). More
patients (p = 0.007) and relatively more patients (p = 0.004)
underwent resections of Stage I and Stage II cancers
2004 through 2010 with commensurately smaller tumors
(p = 0.01).
Conclusions: From 1992 through 2010, progressively more
patients underwent pancreatectomy for pancreatic adenocar-
cinoma with progressively smaller tumors and earlier stages.
These patients lived more years (e.g., improved survival
curves and median survival) but without improved 5-year
survival, denoting better early and intermediate survival.
Early detection, better perioperative care, more efficacious
noncurative chemotherapy undoubtedly play a role, but
better solutions for long-term survival must be sought.
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Background: Since identification of intraductal papillary
mucinous neoplasm (IPMN) in 1996, high-grade dysplasia
and IPMN-associated invasive carcinoma was used fre-
quently under the umbrella term “malignancy”. We aimed to
compare the pathological features and survival outcomes of
high-grade IPMN to invasive carcinoma.
Patients and Methods: From 1996 to 2013 data of 616
patients who underwent pancreatic resection for an IPMN
were reviewed. IPMNs were classified as low/intermediate-,
high-grade dysplasia (HGD), and invasive carcinoma.
Results: A total of 293 (48%) patients diagnosed with low/
intermediate-grade dysplasia, 140 (23%) with HGD, and 183
(30%) with invasive carcinoma. Actual 5-year survival was
55% for the entire cohort. The median overall survival was
94 months for HGD, which was similar to low/intermediate-
grade IPMN (118 months, p = 0.07), and superior to invasive
carcinoma (29 months, p < 0.001) (figure). Invasive carci-
noma was associated with regional lymph node metastasis in
34%, perineural invasion in 38%, and vascular invasion in
38%. In contrast no lymph node metastasis, perineural or
vascular invasion was observed after resection of HGD.
Compared to invasive carcinoma, HGD was associated with
a lower rate of positive margin (38% vs. 24%, p = 0.007).
Among patients who had more than 6 months follow-up, the
recurrence rate after resection of HGD (16%) was similar to
low/intermediate dysplasia (19%, p = 0.50); and was lower
compared to invasive IPMN (29%, p = 0.03).
Conclusion: IPMN with high-grade dysplasia has a
favorable survival outcome and a lower rate of recurrence
after resection compared to IPMN-associated invasive carci-
noma, and thus should not be considered a malignant entity.
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LO-A.04 IRREVERSIBLE
ELECTROPORATION (NANOKNIFE) FOR
PANCREATIC CANCER: A SINGLE
INSTITUTION SERIES OF 50
CONSECUTIVE PATIENTS
K. Mahendraraj, I. Epelboym, B. Schrope, J. A. Chabot,
M. D. Kluger
Department Of Surgery, College Of Physicians And
Surgeons, Columbia University Medical Center, New York,
NEW YORK
Introduction: The NanoKnife® irreversible electroporation
system (IRE) uses electrical energy to destroy neoplastic
tissue invading surrounding neurovascular structures. Large
scale IRE for pancreatic cancer has yet to be reported. This
study examines a large cohort of IRE-treated pancreatic
cancer patients to evaluate the safety of this novel surgical
approach.
Methods: Data was abstracted on all T3 and T4 pancreatic
cancer patients who underwent IRE at a tertiary hepatobiliary
unit from 2012–2014. Standard statistical methodology was
used.
Results: 50 consecutive patients were treated with IRE by 3
pancreatic surgeons, with 36(72%) cases performed by a
single surgeon. Mean patient age was 65.8 ± 7.8 years, with
31(62%) male patients. There were 45(90%) adenocarci-
noma cases, most commonly involving the pancreatic head
(n = 16;32%) or body (n = 16;32%). IRE was used for
primary local control in 25(50%) cases and margin ablation
in 21(42%). Median survival was 11.8 ± 6.2 months. Median
follow-up was 7.8 ± 9.6 months, with length of stay
7.34 ± 5.6 days and readmission rate of 20%(n = 10). 30- and
90-day complication rates were 36%(n = 18) and 6%(n = 3),
most commonly portal vein thrombosis(n = 4;8%), intra-
abdominal collection(n = 3;6%), and anemia requiring
transfusion(n = 3;6%). Overall mortality attributable to IRE
was 6%(n = 3). 3 additional mortalities were related to
disease progression.
Conclusions: IRE offers a feasible technique to manage
advanced pancreatic cancer. To reduce morbidity and mor-
tality, anticoagulation should be considered when performing
IRE near the portal vein, and plastic stenting should be con-
sidered when performing IRE near the common bile duct.
IRE is a potentially crucial tool in the arsenal of surgeons
treating otherwise inoperable pancreatic cancer.
LO-A.05 PRETREATMENT SERUM CA
19-9 LEVELS IN PATIENTS WITH
LOCALIZED PANCREATIC
CANCER TREATED WITH
NEOADJUVANT THERAPY
M. Aldakkak, K. K. Christians, A. N. Krepline, B. George,
P. S. Ritch, B. A. Erickson, F. M. Johnston, D. B. Evans,
S. Tsai
Medical College Of Wisconsin, Milwaukee, WI
Background: Among pancreatic cancer (PC) pts treated
with a surgery-first approach, normal CA19-9 levels have
been associated with improved survival. The impact of
neoadjuvant therapy on this association is unknown.
Methods: Localized PC pts with a CA19-9 level prior to
neoadjuvant therapy were dichotomized into two groups; low
CA19-9 and elevated CA19-9 based on a cutoff of 36 U/mL.
Results: CA19-9 was evaluable in 230 pts prior to any treat-
ment; 57 (25%) were low and 173 (75%) were elevated. The
median CA19-9 level at diagnosis in low and elevated
CA19-9 pts was 14 (IQR:23) and 267 (IQR:594) respec-
tively. Neoadjuvant therapy including successful surgery was
completed in 164 (71%) of the 230 patients; 41 (72%) of 57
low CA19-9 and 123 (71%) of 173 elevated CA19-9 pts
(p = 0.90). Median survival of all 230 pts was 23.8 months;
36.7 months for the 164 pts who completed all therapy
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including surgery vs. 11.7 months for the 66 pts not resected.
Among the 164 pts who completed all therapy, no difference
in median survival was observed between low CA199 and
elevated CA19-9 pts; 36.7 months vs. 33.1 months, p = 0.89.
Conclusions: An elevated CA19-9 at diagnosis did not
predict a failure to complete neoadjuvant therapy and was not
associated with inferior survival. These data suggest two
cautionary notes: an elevated CA19-9 at diagnosis should not
be considered synonymous with advanced (non-surgical)
disease; and, a low/normal CA19-9 should not be interpreted
as a predictor of favorable outcome (and used to justify a
surgery first strategy).
LO-A.06 ONE YEAR EXPERIENCE
OF CHARACTERIZATION OF
GENETIC RISK IN A HIGH-RISK
PANCREATIC CLINIC
K. Flores, K. Dinh, E. Rouleau, W. Wassef, J. LaFemina
University Of Massachusetts, Worcester, MA
Background: Despite the established benefit of early detec-
tion in pancreatic cancer (PDAC) prognosis, high-risk pan-
creatic clinics are less common than their breast or colon
counterparts. One of the difficulties of establishing a high-
risk clinic is delineating which individuals are “high-risk.”
Methods: We retrospectively examined patients referred for
genetic counseling for PDAC from January 2009-June 2014.
Patients were referred for a personal and/or family history of
PDAC or a potential diagnosis of hereditary pancreatitis
(HP).
Results: 75 patients were referred for genetic counseling; 36
underwent testing. Twelve (33%) mutation carriers were
identified, demonstrating a positivity rate higher than in high-
risk clinics for other malignancies. The most common reason
to decline testing was lack of insurance. 11% of patients with
a family history of PDAC were found to carry a mutation.
20% of those a personal history of PDAC were found to carry
a mutation. Ten of 43 patients with a personal history of
chronic pancreatitis were found to carry ≥1 mutations. Of
these, 8 were heterozygous for CFTR mutations, 1 was
CFTR homozygous, and 1 was homozygous for SPINK1
mutations.
Conclusion: This study illustrates criteria for the highest
yield of genetic evaluation for high-risk of PDAC. Insurance
coverage for unaffected relatives is lacking. Identification of
a causative mutation in an affected family member allows for
cost-effective targeted testing in at-risk relatives. Individuals
with apparently idiopathic pancreatitis, onset of pancreati-
tis < 30 years, and those with a family history of pancreatitis
or PDAC are candidates for genetic evaluation.
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ABLATION FOR HEPATOCELLULAR
CARCINOMA LESS THAN 3CM: A
POPULATION BASED ANALYSIS
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Background: Ablation for ≤3 cm hepatocellular carcinoma
(HCC) has been demonstrated to be an effective treatment
strategy. Whether ablation achieves a similar survival benefit
as compared to surgical resection for early stage HCC
remains ill defined. The present study sought to examine the
outcomes of patients with ≤3 cm HCC following ablation
versus resection.
Methods: Patients treated by ablation or surgical resection
for ≤3 cm T1 HCC were identified from the National Cancer
Database (2002–2011). Cox proportional hazards models
were used to assess overall survival (OS) between treatment
types (ablation vs resection) following adjustment for age,
gender, alpha-fetoprotein (AFP), Charlson Comorbidity
Score, and cirrhosis.
Results: A total of 2,855 patients underwent ablation
(n = 1,984) or resection (n = 871) for solitary HCC ≤3 cm.
The median age of the collective cohort was 61 (IQR: 55–70)
with the majority being male (n = 2,007, 70.1%). Patients
treated with ablation as compared to resection had a higher
frequency in AFP elevation (46.5% vs 39%, p < 0.01) and
presence of cirrhosis (22.2% vs 14.9%, p < 0.01). Unad-
justed OS at 3 and 5 years was greater following resection
(67%, 55%) versus ablation (52%, 36%, p < 0.01). In
multivariable models, resection was independently associ-
ated with improved OS (HR: 0.65, 95% CI: 0.51–0.83;
p < 0.01).
Conclusion: While more invasive, resection of HCC ≤3 cm
results in better long-term survival as compared to ablation.
Treatment strategies for small solitary HCC should empha-
size a resection first approach, with ablation being reserved
for patients precluded from surgery.
[Correction added on 24 February 2015. Moved “LO-B.04
“SURGICAL RESECTION VERSUS ABLATION FOR
HEPATOCELLULAR CARCINOMA LESS THAN 3CM: A
POPULATION BASED ANALYSIS” before “LO-B.01”.]
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